Nitroglycerin Patch Shows Modest, Inconsistent Relief for Menopausal Hot Flashes
A systematic review of four small studies finds transdermal nitroglycerin may modestly cut hot flashes, but results are inconsistent and headaches are common.
Summary
Hot flashes affect 75% to 85% of women around menopause, and some women cannot or prefer not to use hormone therapy. A systematic review to be presented at The Menopause Society's 2026 meeting examined continuous transdermal nitroglycerin, a skin patch that dilates blood vessels, as a nonhormone option. Researchers pooled four studies with just over 160 participants. Compared with placebo, results were inconsistent, and in three of four studies the improvements were minimal. One small single-arm study without a placebo group saw hot flash frequency fall by up to 69% at the highest dose, but symptoms returned after stopping. Headaches were the most common side effect, affecting up to two-thirds of participants early in treatment. The authors call the evidence limited, imprecise and inconsistent. The approach is interesting but unproven, and larger well-powered trials are needed before it has a clinical role.
Detailed Summary
Hot flashes are the most frequent symptom of perimenopause and menopause, affecting 75% to 85% of women. They are not life-threatening, but an estimated 10% to 30% of women have symptoms severe enough to impair daily activities, work and quality of life. Night sweats can disrupt sleep and lead to fatigue, irritability and mood changes. Hormone therapy remains the most effective treatment, yet many women cannot or do not want to use it, which is why nonhormone options are multiplying.
This systematic review, to be presented at the 2026 Menopause Society Annual Meeting, evaluated continuous transdermal nitroglycerin. Nitroglycerin releases nitric oxide, a vasodilator, and the idea is that it may influence the blood-vessel and temperature-regulation changes behind hot flashes. The authors reviewed four studies with more than 160 participants in total and assessed hot flash frequency and quality-of-life outcomes.
The findings were mixed. Comparisons with placebo were inconsistent, and in three of four studies any improvements were minimal. A small single-arm study, which had no placebo comparison, reported daily hot flash frequency falling by up to 69% at the maximum dose, but symptoms recurred after treatment stopped. Headaches were the most common adverse event, affecting up to two-thirds of participants early in treatment.
The authors concluded that nitroglycerin patches may offer modest reductions in hot flash frequency and could become a nonhormone option for postmenopausal women with contraindications to hormone therapy. Practically, this is not yet a recommendation. Women with troublesome symptoms who cannot use hormones should discuss established nonhormone options with a clinician, and see this as an early signal rather than a proven therapy.
Caveats are substantial. The evidence base is small and imprecise, the strongest-looking result came from an uncontrolled study, and the placebo-controlled data were largely unimpressive. Headache burden may limit tolerability. Only larger, well-designed trials can clarify efficacy, safety and clinical usefulness. The findings come from a conference presentation and press release, and full details were not yet available.
Key Findings
- Systematic review of four studies, over 160 participants, tested continuous transdermal nitroglycerin for postmenopausal hot flashes.
- Placebo-controlled results were inconsistent; three of four studies showed only minimal improvement.
- One small single-arm study reported up to 69% fewer daily hot flashes at maximum dose, with recurrence after stopping.
- Headache was the most common adverse event, affecting up to two-thirds of participants early in treatment.
- Authors call evidence limited and imprecise; larger well-powered trials are needed before any clinical role.
Methodology
This is a press release on a systematic review to be presented at The Menopause Society's annual meeting, so it is likely not yet peer reviewed. It pooled four studies (over 160 participants) of mixed design, including placebo-controlled trials and one small single-arm study. The source is credible, but the release gives little detail on study quality, doses or effect sizes.
Study Limitations
Evidence is small, imprecise and inconsistent, and the largest reported effect came from an uncontrolled single-arm study. Conference abstract details, risk of bias and long-term safety were not reported in the release. Verify against the full presentation or publication once available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
